A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.
about
Induced Pluripotent Stem Cell as a New Source for Cancer ImmunotherapyDendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?Dendritic cells derived from pluripotent stem cells: Potential of large scale productionRationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionThe dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.Dendritic cell immunotherapy: clinical outcomesInterleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential.Optimizing dendritic cell-based approaches for cancer immunotherapyDendritic cell-based vaccines: barriers and opportunitiesAnti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancerDendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer TherapyHER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restorationHER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.Injectable MMP-sensitive alginate hydrogels as hMSC delivery systems.MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model.A review of dendritic cell therapy for cancer: progress and challenges.Exploiting dendritic cells in the development of cancer vaccines.Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.Dendritic cell-based vaccines: clinical applications in breast cancer.Immunotherapy for the treatment of breast cancer.Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ.Vaccines targeting helper T cells for cancer immunotherapy.Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.Anti-HER2 CD4+ T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer.Modern strategies and capabilities for activation of the immune response against tumor cells.Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancerA pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS.Immunotherapy for Breast Cancer: Current and Future Strategies.Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes.Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies.Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies
P2860
Q26750579-40A1C800-7030-49A9-9309-A6710468317BQ26830857-92DF7C80-E687-482B-AF00-9732BEA4CDDFQ26865622-D018570C-F0F6-4310-8D6D-0638133B952EQ27686800-626639AF-D728-4A29-9BF1-9348B6665C25Q28067145-E3FDCC11-A4A0-4E9F-AC46-4E20C2E2C7F8Q30317628-E1F50112-686A-49A4-A09C-2BC25B9D5E40Q34063596-2EF95249-DFE5-445D-84C5-D9ED0699B5AAQ34511606-50F11890-09C0-48C1-9B66-4333DC90FDD2Q34532389-4C0F2043-166B-4A47-B9EB-51E113FAF4B8Q34637535-18B8B54A-0732-4915-8F9D-3AC6204D2999Q34661797-088EA365-F786-438B-AD2B-4005F6314BF5Q35807188-637D99DD-CF74-4DA2-A2AF-33E07F9CFC59Q35826624-27C19177-7F14-4815-9FF9-44BBB4B0B044Q35899068-159DF8D5-1584-4039-ADEE-DB4362A74E9BQ36107949-82CCC95C-2A6D-4002-A6FF-D678E50F2BE7Q36112574-9F1F4732-D69D-4F8A-B591-8DA0CD36E276Q36487452-0F29688F-5C0E-4D33-ACB2-72A16FC233F1Q36653524-BE4DD76B-4D33-4B43-A253-B3C33BE30E13Q37569930-9C0BFD13-B8B0-4766-9941-F44E2916D278Q37709626-9A6F9E50-1956-4F58-93ED-BC8136980C2FQ37742740-0DFB6FEF-1D66-40C8-A4DB-62BBA2954DEFQ38099612-C1CF1835-8882-4FAE-AB02-E0954A860DE6Q38148774-28DB1769-70C5-4CA9-855E-7F4A9191C269Q38168904-DD8970A6-6D51-4CEB-BAC8-481AB2A87145Q38206821-B1D358C5-E441-4405-BCD3-BAD32C276776Q38353772-4198BC22-E217-40F2-A237-309DA1880DC4Q38648122-C82AF546-DAEC-4302-82E8-A5D5149A958EQ38649958-0409EE1C-2A9C-40B6-9BBA-292C5557D552Q38672403-7C9F34E8-F8D3-4AE7-8A86-F653F0954677Q38948901-F1A86C68-1991-4F77-8514-C2EC9BF72707Q39003439-08DB8F9B-8B86-4C89-8B12-C4939D15A245Q39312666-635734AC-5F16-4CF7-8D18-6253766BB4BCQ41716752-10F58105-010A-458B-8E80-151AB306D638Q45073466-E938A951-AE99-4284-BA55-7EAA78D3E3B5Q48011136-8B842F3A-EB19-4A24-A7D6-1F3594BE45A0Q52587066-BC557C73-5843-4BC7-9FA9-784166AB1BD8Q52909381-D31F014B-D0CD-47C5-8C84-2606FB7C9E03Q55010019-9743BCFD-6320-4C67-8717-6B1F50EB58BFQ57114269-46A4F1C2-0FB5-4D04-A63F-31B2CA0B094E
P2860
A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A novel dendritic cell-based i ...... omen with early breast cancer.
@ast
A novel dendritic cell-based i ...... omen with early breast cancer.
@en
type
label
A novel dendritic cell-based i ...... omen with early breast cancer.
@ast
A novel dendritic cell-based i ...... omen with early breast cancer.
@en
prefLabel
A novel dendritic cell-based i ...... omen with early breast cancer.
@ast
A novel dendritic cell-based i ...... omen with early breast cancer.
@en
P2093
P2860
P1476
A novel dendritic cell-based i ...... women with early breast cancer
@en
P2093
Anupama Sharma
Brian J Czerniecki
Bruce L Levine
Elizabeth Fitzpatrick
Gary K Koski
Harvey Nisenbaum
Paul Zhang
Rosemarie Mick
P2860
P356
10.1097/CJI.0B013E318235F512
P577
2012-01-01T00:00:00Z